EDITORIAL
Accepted on 29 Jan 2025
Editorial: Ovarian Cancer Targeted Medication: PARP Inhibitors, Anti-Angiogenic Drugs, Immunotherapy, and More -Volume II
doi 10.3389/fphar.2025.1552652
- Frontiers in Pharmacology
- Pharmacology of Anti-Cancer Drugs
- Research Topics
- Ovarian Cancer Targeted Medication: PARP Inhibitors, Anti-Angiogenic Drugs, Immunotherapy, and More, volume II
Ovarian Cancer Targeted Medication: PARP Inhibitors, Anti-Angiogenic Drugs, Immunotherapy, and More, volume II
10k
Total downloads
33k
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
REVIEW
Published on 05 Nov 2024
Emerging strategies to overcome ovarian cancer: advances in immunotherapy
doi 10.3389/fphar.2024.1490896
- 917 views
SYSTEMATIC REVIEW
Published on 18 Sep 2024
Efficacy and safety of PARP inhibitor maintenance therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials
doi 10.3389/fphar.2024.1460285
- 976 views
SYSTEMATIC REVIEW
Published on 12 Sep 2024
Mapping and visualization of global research progress on deubiquitinases in ovarian cancer: a bibliometric analysis
doi 10.3389/fphar.2024.1445037
- 869 views
BRIEF RESEARCH REPORT
Published on 07 Aug 2024
The first-in-class pro-apoptotic peptide PEP-010 is effective in monotherapy and in combination with paclitaxel on resistant ovarian adenocarcinoma cell models
doi 10.3389/fphar.2024.1444973
- 1,156 views
SYSTEMATIC REVIEW
Published on 30 Jul 2024
Past and present: a bibliometric study on the treatment of recurrent ovarian cancer
doi 10.3389/fphar.2024.1442022
- 803 views
- 1 citation
PERSPECTIVE
Published on 01 Jul 2024
Lipid droplets: a candidate new research field for epithelial ovarian cancer
doi 10.3389/fphar.2024.1437161
- 715 views
ORIGINAL RESEARCH
Published on 17 Jun 2024
Real-world TRAE association between niraparib and platinum-based chemotherapy
doi 10.3389/fonc.2024.1390820
- 689 views
REVIEW
Published on 14 Jun 2024
New hopes and promises in the treatment of ovarian cancer focusing on targeted treatment—a narrative review
doi 10.3389/fphar.2024.1416555
- 2,484 views
- 3 citations
ORIGINAL RESEARCH
Published on 04 Jun 2024
Identification of potential novel N6-methyladenosine effector-related lncRNA biomarkers for serous ovarian carcinoma: a machine learning-based exploration in the framework of 3P medicine
doi 10.3389/fphar.2024.1351929
- 866 views
ORIGINAL RESEARCH
Published on 27 May 2024
Efficacy and safety of anti-angiogenic drug monotherapy and combination therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials
doi 10.3389/fphar.2024.1423891
- 697 views
- 1 citation
ORIGINAL RESEARCH
Published on 20 May 2024
Enhanced amphiregulin exposure promotes modulation of the high grade serous ovarian cancer tumor immune microenvironment
doi 10.3389/fphar.2024.1375421
- 1,379 views
- 3 citations
Published in
Frontiers in Pharmacology
- Pharmacology of Anti-Cancer Drugs
- Experimental Pharmacology and Drug Discovery
Participating Journals
Frontiers in Oncology
- 3.5 impact factor
- 6.2 citescore
Impact
- 33kTopic views
- 21kArticle views
- 10kArticle downloads